The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Blinatumomab consolidation therapy for DLBCL
John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, outlines the results of a pilot study (NCT03072771) which tested blinatumomab as a consolidation therapy post-autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with diffuse large B-cell lymphoma (DLBCL). The study showed that blinatumomab consolidation was safe and well tolerated, and 100 days post auto-HSCT (one month post blinatumomab consolidation) 10/10 patients were in complete remission. After a median of 14.5 months of follow-up, 6 patients remained in remission. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
